Reporting dated May 30 states that researchers reported blocking the GPNMB protein responsible for spreading toxic immune cells in neural tissues.
Researchers blocked the GPNMB protein implicated in spreading toxic immune cells in Parkinson’s brain tissue.
Separately, the clinical trial mapped inflammatory pathways that accelerate neurodegenerative progression.
Targeting GPNMB reduced immune-mediated neural damage in study models. The account draws on verified materials available as of May 30, 2026.
Scientists said the approach requires further human trials before therapeutic application. Further updates are expected as proceedings continue.
Named entities in source reporting include GPNMB, Parkinson’s researchers.
Source documents list dates, agencies, and procedural steps referenced in the summary above.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/news/health_medicine/parkinsons-protein-block-33